Cencora, Inc. ((COR)) has held its Q2 earnings call. Read on for the main highlights of the call.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Cencora’s latest earnings call struck a cautiously upbeat tone as management paired solid profit growth with a notable cut to revenue guidance. Executives emphasized resilient margins, strong cash generation, and higher EPS targets, arguing that current revenue headwinds from pricing and customer shifts are transitory rather than structural.
Adjusted EPS Growth and Upgraded Full-Year Outlook
Cencora reported adjusted diluted EPS of $4.75 for Q2, a 7.5% increase from a year earlier that underscored effective cost control and mix improvements. On the back of this performance, management raised full-year adjusted EPS guidance to a range of $17.65 to $17.90, signaling confidence in earnings power despite softer top-line growth.
Gross Profit Strength and Margin Expansion
Consolidated gross profit climbed 16% year-over-year to $3.4 billion, with gross margin improving 45 basis points to 4.31%. The step-up in profitability was helped by the OneOncology acquisition and a richer mix of higher-margin services, partially offsetting volume and pricing pressures in the core distribution business.
Operating Income and Segment-Level Profitability
Consolidated operating income rose 6% to $1.3 billion, highlighting leverage in the company’s operating model. U.S. Healthcare Solutions delivered 6% operating income growth to $998 million, while International Healthcare Solutions posted roughly 14% operating income growth as reported, or about 13% in constant currency.
International and Global Specialty Momentum
International Healthcare Solutions revenue increased 13% as reported to $7.6 billion, or 7% in constant currency, underscoring solid demand abroad. Global specialty logistics delivered a second straight quarter of operating income growth, fueled by new contracts in cell and gene therapies and expanding laboratory logistics capabilities.
Robust Cash Generation and Shareholder Returns
The company ended the quarter with $2.2 billion in cash after generating $1.1 billion of free cash flow, keeping it on track for about $3.0 billion in adjusted free cash flow for the year. Management also restarted opportunistic share repurchases, targeting $1.0 billion of buybacks by year-end and guiding to a diluted share count below 195.5 million.
Improved Operating Income Guidance
Management raised full-year consolidated operating income growth guidance to 12% to 14%, up from 11.5% to 13.5%, highlighting confidence in margin durability. Within that, U.S. Healthcare Solutions is still expected to grow operating income by 14% to 16%, reinforcing the segment’s role as the primary earnings engine.
Revenue Growth Guidance Cut Back
In contrast, consolidated revenue growth guidance was reduced sharply to 4% to 6%, down from the prior 7% to 9% range. U.S. Healthcare Solutions revenue expectations were also cut to 4% to 6%, reflecting faster-than-anticipated branded drug conversions and slower growth in GLP-1 therapies.
Headwinds from Price Reductions and Customer Changes
Manufactured list price reductions created a $2.0 billion revenue headwind in the quarter, weighing on reported top-line growth. Additional pressure came from the previously disclosed loss of an oncology customer and a grocery customer, while accelerated brand conversions at a large mail-order customer hurt revenue but improved overall mix and margins.
Higher Operating Expenses from OneOncology Deal
Consolidated operating expenses jumped 22.5% to $2.1 billion, largely due to the integration of the OneOncology acquisition completed in February 2026. Stripping out MSO activity linked to that deal and currency effects, underlying operating expenses grew by about 5%, suggesting core cost discipline remains intact.
Rising Interest Expense and Debt Costs
Net interest expense increased to $140 million in the quarter, up $36 million year-over-year, reflecting debt issued to fund the OneOncology purchase. For the full year, the company now expects approximately $485 million in interest expense, with Q3 interest costs projected to be roughly in line with Q2 levels.
Temporary Operating Headwinds and One-Off Effects
Management flagged several transient drags on Q2 performance, including an estimated $10 million hit to operating income from severe weather that reduced patient appointments. Another $10 million headwind came from the tough comparison against prior-year COVID-19 vaccine contributions, which have now normalized.
Other Segment Margin Pressure Despite Revenue Growth
The company’s Other segment generated $2.1 billion of revenue, up 5%, but operating income slipped 1% to $92 million. Executives attributed the slight profit decline mainly to weaker U.S. hub consulting services, partly offset by growth at MWI Animal Health, indicating mixed trends across ancillary businesses.
Outlook and Guidance Emphasize Profits Over Revenue
Looking ahead, Cencora now projects consolidated revenue growth of 4% to 6%, with U.S. revenue in the same band and International revenue expected to rise 8% to 10% as reported, or 6% to 8% in constant currency. Consolidated operating income is forecast to grow 12% to 14%, International operating income 5% to 8%, Other in the high single digits, and adjusted EPS in the high single digits in Q3 with the strongest earnings cadence in Q4, supported by about $3.0 billion in free cash flow and ongoing share repurchases.
Cencora’s earnings call painted a picture of a company managing through top-line turbulence while protecting and even enhancing profitability. For investors, the key takeaway is that earnings, margins, and cash returns are moving in the right direction, even as revenue growth resets lower due to pricing and customer mix shifts that management insists are largely temporary.